Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

Stopped early · Phase 2

Conditions studied: Head and Neck Squamous Cell Carcinoma

In brief

The goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in participants with head and neck squamous cell carcinoma (HNSCC).

Key facts

Study ID
NCT04854499
Run by
Gilead Sciences
People needed
193
Starts
2021-09-07
Expected to finish
2024-10-02
Last updated by the study team
2025-11-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.